Developing new treatments for respiratory viruses and emerging infections
Respi-DART: Frontiers in drug development against respiratory viruses and emerging viruses
This study is bringing together doctors and scientists to share ideas and discoveries about new treatments for respiratory viruses like COVID-19, with the goal of improving care for people who are most at risk.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11074833 on NIH RePORTER |
What this research studies
This research focuses on advancing antiviral therapies for respiratory viruses, including COVID-19, by bringing together experts from various fields such as medicine, biology, and public health. The project will host workshops where clinicians and scientists can share the latest findings and discuss challenges in drug development and vaccine creation. By fostering collaboration and knowledge exchange, the initiative aims to enhance the understanding and treatment of respiratory infections that significantly impact vulnerable populations.
Who could benefit from this research
Good fit: Ideal candidates for this research include adults, particularly those at higher risk for respiratory infections, such as the elderly or individuals with compromised immune systems.
Not a fit: Patients who are not adults or those without any risk factors for respiratory infections may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective antiviral treatments and vaccines for respiratory viruses, improving health outcomes for patients.
How similar studies have performed: Previous research initiatives focused on antiviral therapies have shown success in improving treatment options for various viral infections, indicating a promising outlook for this approach.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Schinazi, Raymond Felix — Emory University
- Study coordinator: Schinazi, Raymond Felix
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.